Pre-operative SN mapping with radionucleide

Phase 3Small molecule

Pre-operative SN mapping with radionucleide is one of 52 small molecule programs targeting Endometrial Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endometrial CarcinomaActive, not recruiting

Endometrial CarcinomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Endometrial Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

6 2

Lenvima

Eisai

Phase 3

5 3

Depo-Provera

Eli Lilly

Phase 3

1 4

Paraplatin

AAvyxa

Phase 3

6 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 6

Herceptin

OOrganon and Co

Phase 3

1 7

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

1 8

Keytruda

Merck & Co.

Phase 2

5 9

Megace

Bristol-Myers Squibb

Phase 2

3 10

Femara

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Endometrial Carcinoma

NCT02598219

Clinical

Trials by Indication[1]

Endometrial Carcinoma1 trial

Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.

Active, not recruiting·CCentre Oscar Lambret·Phase 3·NCT02598219·262 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pre-operative SN mapping with radionucleide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pre-operative SN mapping with radionucleide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pre-operative SN mapping with radionucleide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Centre Oscar Lambret company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CCentre Oscar Lambret

Pre-operative SN mapping with radionucleide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Endometrial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News